Prosecution Insights
Last updated: April 19, 2026
Application No. 18/134,751

In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof

Non-Final OA §102§112
Filed
Apr 14, 2023
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kaunas University Of Technology
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 11m
To Grant
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
869 granted / 1225 resolved
+10.9% vs TC avg
Minimal +0% lift
Without
With
+0.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
43 currently pending
Career history
1268
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
14.6%
-25.4% vs TC avg
§102
29.8%
-10.2% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1225 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant's election with traverse of Group I, and species below, in the reply filed on December 22, 2025 is acknowledged. The traversal is on the ground(s) that Groups I and II should be considered one invention because both compound and polymer have the same crosslinkable Z. This is not found persuasive because the products are distinct for the reasons provided in the restriction requirement. The products have structural features that have materially different design. Nonetheless, when the products of the elected Group I become allowable, Examiner may consider rejoining the products of Group II that incorporate the structural features of the allowable Group I. The requirement is still deemed proper and is therefore made FINAL. 3. Examination followed guidelines provided by MPEP 803.02. The elected species appeared to be novel and nonobvious over the prior art. Therefore the search was extended. Prior art was found that anticipates the Markush claims with respect to a nonelected species. Therefore, the Markush claims were rejected and claims to nonelected species were withdrawn from further consideration. The claims were searched to the extent of the elected species and the nonelected species shown below. Status of Claims 4. Claims 1-24 are pending. Claims 1-3 are elected and read on the elected species. Claim 1 is independent. All elected claims are rejected. Information Disclosure Statement 5. The information disclosure statement (IDS) submitted on April 14, 2023 is in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS was considered. A signed copy of form 1449 is enclosed herewith. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 6. Claim 3 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claim refers to “ PNG media_image1.png 64 528 media_image1.png Greyscale PNG media_image2.png 30 242 media_image2.png Greyscale . It is unclear how a dotted line can represent a single bond between the 9,9’-spirobifluorene core. Variable Z is not connected to the 9,9’-spirobifluorene core directly because X connects Z to the core. Appropriate clarification and correction are requested. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 7. Claim(s) 1-3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2012003485. The reference has a publication date of 2012 which antedates the present claims having a filing date of 2023. The reference teaches compounds such as PNG media_image3.png 272 320 media_image3.png Greyscale which corresponds to the claims in the following manner: X=phenyl/phenyl substituted with alkyl; a=1; b=0; Z=C2 alkenyl. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Apr 14, 2023
Application Filed
Mar 05, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595251
AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS
2y 5m to grant Granted Apr 07, 2026
Patent 12594266
TRITERPENOID ANTIFUNGALS FOR THE TREATMENT OR PREVENTION OF PNEUMOCYSTIS SPP. PNEUMONIA
2y 5m to grant Granted Apr 07, 2026
Patent 12583854
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12583855
RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583821
SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.4%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 1225 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month